Optimism in inclusion body myositis: a double-blind randomised controlled phase III trial investigating the effect of sirolimus on disease progression in patients with IBM as measured by the IBM Functional Rating Scale

This phase IIb/III trial builds on prior findings to assess sirolimus's potential in slowing or halting IBM progression, preserving patient function and independence, and advancing IBM therapeutic strategies and trial design.

Authors

Institutions

Publication Details

Journal
Clinical and Experimental Rheumatology
Published
2025-02-26
DOI
https://doi.org/10.55563/clinexprheumatol/zvffa0
Citations
3
Primary Topic
Inflammatory Myopathies and Dermatomyositis
Type
article
Field-Weighted Citation Impact
4.06
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Optimism in inclusion body myositis: a double-blind randomised controlled phase III trial investigating the effect of sirolimus on disease progression in patients with IBM as measured by the IBM Functional Rating Scale

Ian Cooper, Christine Lowe, Kelly Beer, Christina Liang et al.
3 citations
Clinical and Experimental Rheumatology
Inflammatory Myopathies and Dermatomyositis
4.06
article

Optimism in inclusion body myositis: a double-blind randomised controlled phase III trial investigating the effect of sirolimus on disease progression in patients with IBM as measured by the IBM Functional Rating Scale

Ian Cooper, Christine Lowe, Kelly Beer, Christina Liang, Antonia Carroll, Doris Chan, Katrina Reardon, Max Bulsara, Lauren Sanders, Anna Brusch, Thomas E. Lloyd, Roula Ghaoui, Krystyne Hiscock, Jens Schmidt, Robert D. Henderson, Mazen M. Dimachkie, Merrilee Needham, Stefen Brady, Umesh A. Badrising, Anneke J. van der Kooi, Michael McDermott, Matthew C. Kiernan, Aneesya Panicker, Andrew J. Heim, Marion Simpson, Payam Mohassel, Timothy J. Fairchild, Jérôme D. Coudert, Alastair Corbett, Stephen Reddel, Dag Leonard, Althea Doverty, Gayatri Jain, Marjolein van Heur-Neuman, Chris Weihl, Olivier Benveniste, Susan Walters
article en
3 citations

Abstract

This phase IIb/III trial builds on prior findings to assess sirolimus's potential in slowing or halting IBM progression, preserving patient function and independence, and advancing IBM therapeutic strategies and trial design.

Clinical and Experimental RheumatologyVol. 43(2)
Uppsala University (SE), The University of Sydney (AU), Johns Hopkins University (US), Royal Prince Alfred Hospital (AU), Johns Hopkins Medicine (US), Leiden University Medical Center (NL), Austin Hospital (AU), Sir Charles Gairdner Hospital (AU), St Vincent's Hospital Melbourne (AU), University of Kansas Medical Center (US), Perron Institute for Neurological and Translational Science (AU), Austin Health (AU), The University of Notre Dame Australia (AU)
Reduced inequalities
Openalex Percentile: Top 7%
Inflammatory Myopathies and Dermatomyositis
4.06
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.